HRP20201769T1 - Spojevi 1-fenilpropanona i njihove uporabe - Google Patents

Spojevi 1-fenilpropanona i njihove uporabe Download PDF

Info

Publication number
HRP20201769T1
HRP20201769T1 HRP20201769TT HRP20201769T HRP20201769T1 HR P20201769 T1 HRP20201769 T1 HR P20201769T1 HR P20201769T T HRP20201769T T HR P20201769TT HR P20201769 T HRP20201769 T HR P20201769T HR P20201769 T1 HRP20201769 T1 HR P20201769T1
Authority
HR
Croatia
Prior art keywords
compound
phenyl
propan
methylpiperazin
piperidin
Prior art date
Application number
HRP20201769TT
Other languages
English (en)
Inventor
Giuseppe Zagotto
Giovanni RIBAUDO
Anna Maria BRUNATI
Mario Angelo Primo PAGANO
Elena TIBALDI
Livio TRENTIN
Original Assignee
Universita' Degli Studi Di Padova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita' Degli Studi Di Padova filed Critical Universita' Degli Studi Di Padova
Publication of HRP20201769T1 publication Critical patent/HRP20201769T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F11/00—Compounds containing elements of Groups 6 or 16 of the Periodic Table

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Claims (15)

1. Spoj 1-fenilpropanona formule (I) [image] ili njegova farmaceutski prihvatljiva sol pri čemu: X je metilen skupina (-CH2-) ili atom odabran od skupine koja se sastoji od O, S i Se, n je cijeli broj od 4 do 6, A je supstituent odabran od skupine koja se sastoji od 4-morfolila, 1-piperidinila i 4-metil-1-piperazinila, te je izborno supstituiran s (C1-C3)alkilom ili (C1-C3)acil radikalom, uz uvjet da kad X je CH2, n je jednak 5, za uporabu kao antitumorski agens u liječenju raka dojke, kronične limfocitne leukemije ili neuroblastoma.
2. Spoj za uporabu prema zahtjevu 1, pri čemu X je S, Se ili CH2, poželjno S.
3. Spoj za uporabu prema zahtjevu 1 ili 2, pri čemu n je 5 ili 6.
4. Spoj za uporabu prema zahtjevu 1, pri čemu je spomenuti spoj odabran od skupine koja se sastoji od: Spoj 1 (AF08), 1-(4-(heksiloksi)fenil)-3-morfolinopropan-1-on, Spoj 2 (CC11) 1-(4-(heptiloksi)fenil)-3-morfolinopropan-1-on Spoj 3 (AF07), 1-(4-(heksiloksi)fenil)-3-(piperidin-1-il)propan-1-on, Spoj 4 (CC12), 1-(4-(heptiloksi)fenil)-3-(piperidin-1-il)propan-1-on, Spoj 5 (AI01), 1-(4-(heptiloksi)fenil)-3-(4-metilpiperazin-1-il)propan-1-on, Spoj 6 (MD63), 3-morfolino-1-(4-(pentiltio)fenil)propan-1-on, Spoj 7 (VP158), 1-(4-(heksiltio)fenil)-3-morfolinopropan-1-on, Spoj 8 (FT017), 1-(4-(heptiltio)fenil)-3-morfolinopropan-1-on, Spoj 9 (MC12), 1-(4-(pentiltio)fenil)-3-(piperidin-1-il)propan-1-on, Spoj 10 (VP157), 1-(4-(heksiltio)fenil)-3-(piperidin-1-il)propan-1-on, Spoj 11 (FT018), 1-(4-(heptiltio)fenil)-3-(piperidin-1-il)propan-1-on, Spoj 12 (FT013), 3-(4-metilpiperazin-1-il)-1-(4-(pentiltio)fenil)propan-1-on, Spoj 13 (FT016), 1-(4-(heksiltio)fenil)-3-(4-metilpiperazin-1-il)propan-1-on, Spoj 14 (FT019), 1-(4-(heptiltio)fenil)-3-(4-metilpiperazin-1-il)propan-1-on, Spoj 15 (GR376), 3-morfolino-1-(4-(pentilselenil)fenil)propan-1-on, Spoj 16 (GR377), 1-(4-(heksilselenil)fenil)-3-morfolinopropan-1-on, Spoj 17 (GR386), 1-(4-(heptilselenil)fenil)-3-morfolinopropan-1-on, Spoj 18 (GR378), 1-(4-(pentilselenil)fenil)-3-(piperidin-1-il)propan-1-on, Spoj 19 (GR381), 1-(4-(heksilselenil)fenil)-3-(piperidin-1-il)propan-1-on, Spoj 20 (GR387), 1-(4-(heptilselenil)fenil)-3-(piperidin-1-il)propan-1-on, Spoj 21 (GR379), 3-(4-metilpiperazin-1-il)-1-(4-(pentilselenil)fenil)propan-1-on, Spoj 22 (GR383), 1-(4-(heksilselenil)fenil)-3-(4-metilpiperazin-1-il)propan-1-on, Spoj 23 (GR388), 1-(4-(heptilselenil)fenil)-3-(4-metilpiperazin-1-il)propan-1-on, Spoj 24 (GR390), 1-(4-heptilfenil)-3-morfolinopropan-1-on, Spoj 25 (GR391), 1-(4-heptilfenil)-3-(piperidin-1-il)propan-1-on, te Spoj 26 (GR392), 1-(4-heptilfenil)-3-(4-metilpiperazin-1-il)propan-1-on.
5. Spoj 1-fenilpropanona formule (I) [image] ili njegova farmaceutski prihvatljiva sol pri čemu: X je metilen skupina (-CH2-) ili atom odabran od skupine koja se sastoji od O, S i Se, n je cijeli broj od 4 do 6, A je supstituent odabran od skupine koja se sastoji od 4-morfolila, 1-piperidinila i 4-metil-1-piperazinila, te je izborno supstituiran s (C1-C3)alkilom ili (C1-C3)acil radikalom, uz uvjet da kad X je O, A je 4-metil-1-piperazinil, te n je jednak 6, kad X je S i n je 5, tad A je 4-metil-1-piperazinil, kad X je Se i A je 1-piperidinil, tad n je 6, kad X je CH2, n je jednak 5, te A je 4-metil-1-piperazinil ili 4-morfolil.
6. Spoj za uporabu prema zahtjevu 5, pri čemu X je odabran od skupine koja se sastoji od S, Se ili CH2, poželjno S.
7. Spoj za uporabu prema zahtjevu 5 ili 6, pri čemu n je 5 ili 6.
8. Spoj prema zahtjevu 6, pri čemu je spomenuti spoj odabran od skupine koja se sastoji od: Spoj 5 (AI01), 1-(4-(heptiloksi)fenil)-3-(4-metilpiperazin-1-il)propan-1-on, Spoj 6 (MD63), 3-morfolino-1-(4-(pentiltio)fenil)propan-1-on, Spoj 8 (FT017), 1-(4-(heptiltio)fenil)-3-morfolinopropan-1-on, Spoj 9 (MC12), 1-(4-(pentiltio)fenil)-3-(piperidin-1-il)propan-1-on, Spoj 11 (FT018), 1-(4-(heptiltio)fenil)-3-(piperidin-1-il)propan-1-on, Spoj 12 (FT013), 3-(4-metilpiperazin-1-il)-1-(4-(pentiltio)fenil)propan-1-on, Spoj 13 (FT016), 1-(4-(heksiltio)fenil)-3-(4-metilpiperazin-1-il)propan-1-on, Spoj 14 (FT019), 1-(4-(heptiltio)fenil)-3-(4-metilpiperazin-1-il)propan-1-on, Spoj 15 (GR376), 3-morfolino-1-(4-(pentilselenil)fenil)propan-1-on, Spoj 16 (GR377), 1-(4-(heksilselenil)fenil)-3-morfolinopropan-1-on, Spoj 17 (GR386), 1-(4-(heptilselenil)fenil)-3-morfolinopropan-1-on, Spoj 20 (GR387), 1-(4-(heptilselenil)fenil)-3-(piperidin-1-il)propan-1-on, Spoj 21 (GR379), 3-(4-metilpiperazin-1-il)-1-(4-(pentilselenil)fenil)propan-1-on, Spoj 22 (GR383), 1-(4-(heksilselenil)fenil)-3-(4-metilpiperazin-1-il)propan-1-on, Spoj 23 (GR388), 1-(4-(heptilselenil)fenil)-3-(4-metilpiperazin-1-il)propan-1-on, Spoj 24 (GR390), 1-(4-heptilfenil)-3-morfolinopropan-1-on, te Spoj 26 (GR392), 1-(4-heptilfenil)-3-(4-metilpiperazin-1-il)propan-1-on.
9. Spoj prema zahtjevu 8, pri čemu je spomenuti spoj odabran od skupine koja se sastoji od: Spoj 5 (AI01), 1-(4-(heptiloksi)fenil)-3-(4-metilpiperazin-1-il)propan-1-on, Spoj 8 (FT017), 1-(4-(heptiltio)fenil)-3-morfolinopropan-1-on, Spoj 9 (MC12), 1-(4-(pentiltio)fenil)-3-(piperidin-1-il)propan-1-on, Spoj 11 (FT018), 1-(4-(heptiltio)fenil)-3-(piperidin-1-il)propan-1-on, Spoj 13 (FT016), 1-(4-(heksiltio)fenil)-3-(4-metilpiperazin-1-il)propan-1-on, Spoj 14 (FT019), 1-(4-(heptiltio)fenil)-3-(4-metilpiperazin-1-il)propan-1-on, Spoj 17 (GR386), 1-(4-(heptilselenil)fenil)-3-morfolinopropan-1-on, Spoj 20 (GR387), 1-(4-(heptilselenil)fenil)-3-(piperidin-1-il)propan-1-on, Spoj 23 (GR388), 1-(4-(heptilselenil)fenil)-3-(4-metilpiperazin-1-il)propan-1-on, Spoj 24 (GR390), 1-(4-heptilfenil)-3-morfolinopropan-1-on, te Spoj 26 (GR392), 1-(4-heptilfenil)-3-(4-metilpiperazin-1-il)propan-1-on.
10. Spoj formule (I) [image] ili njegova farmaceutski prihvatljiva sol pri čemu: X je metilen skupina (-CH2-) ili atom odabran od skupine koja se sastoji od O, S i Se, n je cijeli broj od 4 do 6, A je supstituent odabran od skupine koja se sastoji od 4-morfolila, 1-piperidinila i 4-metil-1-piperazinila, te je izborno supstituiran s (C1-C3)alkilom ili (C1-C3)acil radikalom, uz uvjet da kad X je O, A je 4-metil-1-piperazinil, te n je jednak 6, kad X je S i n je 5, tad A je 4-metil-1-piperazinil ili 4-morfolil, 5 kad X je Se i A je 1-piperidinil, tad n je 6, kad X je CH2, n je jednak 5, te A je 4-metil-1-piperazinil ili 4-morfolil, za uporabu kao lijek.
11. Farmaceutski sastav koji sadrži spoj prema formuli iz zahtjeva 10 ili njegovu farmaceutski prihvatljivu sol i farmaceutski prihvatljivi nosač za uporabu kao lijek.
12. Spoj formule (I) [image] ili njegova farmaceutski prihvatljiva sol pri čemu: X je metilen skupina (-CH2-) ili atom odabran od skupine koja se sastoji od O, S i Se, n je cijeli broj od 4 do 6, A je supstituent odabran od skupine koja se sastoji od 4-morfolila, 1-piperidinila i 4-metil-1-piperazinila, te je izborno supstituiran s (C1-C3)alkilom ili (C1-C3)acil radikalom, uz uvjet da kad X je O, A je 4-metil-1-piperazinil ili 1-piperidinil, te n je jednak 6, kad X je CH2, n je 5 za uporabu kao antitumorski agens.
13. Spoj za uporabu prema zahtjevu 12, pri čemu je antitumorsko liječenje protiv raka dojke, hepatokarcinoma, kronične limfocitne leukemije ili neuroblastoma.
14. Spoj za uporabu prema zahtjevu 12 ili 13, pri čemu je X odabran od skupine koja se sastoji od S, Se ili CH2, poželjno S.
15. Spoj za uporabu prema zahtjevu 12, pri čemu je spoj 1-fenilpropanona odabran od skupine koja se sastoji od: Spoj 4 (CC12), 1-(4-(heptiloksi)fenil)-3-(piperidin-1-il)propan-1-on, Spoj 5 (AI01), 1-(4-(heptiloksi)fenil)-3-(4-metilpiperazin-1-il)propan-1-on, Spoj 6 (MD63), 3-morfolino-1-(4-(pentiltio)fenil)propan-1-on, Spoj 7 (VP158), 1-(4-(heksiltio)fenil)-3-morfolinopropan-1-on, Spoj 8 (FT017), 1-(4-(heptiltio)fenil)-3-morfolinopropan-1-on, Spoj 9 (MC12), 1-(4-(pentiltio)fenil)-3-(piperidin-1-il)propan-1-on, Spoj 10 (VP157), 1-(4-(heksiltio)fenil)-3-(piperidin-1-il)propan-1-on, Spoj 11 (FT018), 1-(4-(heptiltio)fenil)-3-(piperidin-1-il)propan-1-on, Spoj 12 (FT013), 3-(4-metilpiperazin-1-il)-1-(4-(pentiltio)fenil)propan-1-on, Spoj 13 (FT016), 1-(4-(heksiltio)fenil)-3-(4-metilpiperazin-1-il)propan-1-on, Spoj 14 (FT019), 1-(4-(heptiltio)fenil)-3-(4-metilpiperazin-1-il)propan-1-on, Spoj 15 (GR376), 3-morfolino-1-(4-(pentilselenil)fenil)propan-1-on, Spoj 16 (GR377), 1-(4-(heksilselenil)fenil)-3-morfolinopropan-1-on, Spoj 17 (GR386), 1-(4-(heptilselenil)fenil)-3-morfolinopropan-1-on, Spoj 18 (GR378), 1-(4-(pentilselenil)fenil)-3-(piperidin-1-il)propan-1-on, Spoj 19 (GR381), 1-(4-(heksilselenil)fenil)-3-(piperidin-1-il)propan-1-on, Spoj 20 (GR387), 1-(4-(heptilselenil)fenil)-3-(piperidin-1-il)propan-1-on, Spoj 21 (GR379), 3-(4-metilpiperazin-1-il)-1-(4-(pentilselenil)fenil)propan-1-on, Spoj 22 (GR383), 1-(4-(heksilselenil)fenil)-3-(4-metilpiperazin-1-il)propan-1-on, Spoj 23 (GR388), 1-(4-(heptilselenil)fenil)-3-(4-metilpiperazin-1-il)propan-1-on, Spoj 24 (GR390), 1-(4-heptilfenil)-3-morfolinopropan-1-on, Spoj 25 (GR391), 1-(4-heptilfenil)-3-(piperidin-1-il)propan-1-on, te Spoj 26 (GR392), 1-(4-heptilfenil)-3-(4-metilpiperazin-1-il)propan-1-on.
HRP20201769TT 2016-09-30 2020-11-02 Spojevi 1-fenilpropanona i njihove uporabe HRP20201769T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102016000098338A IT201600098338A1 (it) 2016-09-30 2016-09-30 Composti 1-fenilpropanone e loro impiego
EP17791160.9A EP3518927B9 (en) 2016-09-30 2017-09-29 1-phenylpropanone compounds and use thereof
PCT/IB2017/056010 WO2018060947A1 (en) 2016-09-30 2017-09-29 1-phenylpropanone compounds and use thereof

Publications (1)

Publication Number Publication Date
HRP20201769T1 true HRP20201769T1 (hr) 2021-03-19

Family

ID=57960639

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201769TT HRP20201769T1 (hr) 2016-09-30 2020-11-02 Spojevi 1-fenilpropanona i njihove uporabe

Country Status (19)

Country Link
US (1) US11345673B2 (hr)
EP (1) EP3518927B9 (hr)
JP (1) JP7016370B2 (hr)
CN (1) CN110035753B (hr)
AU (1) AU2017335421A1 (hr)
BR (1) BR112019006565A2 (hr)
CA (1) CA3038008A1 (hr)
DK (1) DK3518927T3 (hr)
ES (1) ES2830749T3 (hr)
HR (1) HRP20201769T1 (hr)
HU (1) HUE052039T2 (hr)
IL (1) IL265617B (hr)
IT (1) IT201600098338A1 (hr)
LT (1) LT3518927T (hr)
PT (1) PT3518927T (hr)
RS (1) RS61109B1 (hr)
RU (1) RU2765102C2 (hr)
SI (1) SI3518927T1 (hr)
WO (1) WO2018060947A1 (hr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54125630A (en) * 1978-02-22 1979-09-29 Nippon Zoki Pharmaceutical Co Novel propanone derivative*its manufacture and medical composition containing it as active component
DE2842091A1 (de) * 1978-09-27 1980-04-10 Dow Chemical Co Verfahren zur inaktivierung behuellter viren
JPS5549317A (en) * 1978-10-02 1980-04-09 Dow Chemical Co Control of virus surrounded with phenylketones
US4931473A (en) * 1989-02-15 1990-06-05 Richardson-Vicks Inc. Anesthetic oral compositions
AU7847800A (en) 1999-10-15 2001-04-30 Mayo Foundation For Medical Education And Research Topical anesthetics useful for treating cancer, autoimmune diseases and ischemia
ES2414205T3 (es) * 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
FR2902789A1 (fr) * 2006-06-21 2007-12-28 Genfit Sa Derives de 1,3-diphenylpropane substitues, preparations et utilisations
US20100285001A1 (en) * 2007-10-02 2010-11-11 University Of Rochester Method and Compositions Related to Synergistic Responses to Oncogenic Mutations
US8309768B2 (en) * 2010-11-29 2012-11-13 The Ohio State University Research Foundation FTY720-derived anticancer agents

Also Published As

Publication number Publication date
JP7016370B2 (ja) 2022-02-21
RU2019113064A3 (hr) 2020-10-30
WO2018060947A1 (en) 2018-04-05
EP3518927A1 (en) 2019-08-07
IL265617B (en) 2022-01-01
EP3518927B1 (en) 2020-08-12
EP3518927B9 (en) 2021-04-07
JP2019529576A (ja) 2019-10-17
DK3518927T3 (da) 2020-11-09
PT3518927T (pt) 2020-11-12
CN110035753B (zh) 2022-08-05
RS61109B1 (sr) 2020-12-31
AU2017335421A1 (en) 2019-05-16
CN110035753A (zh) 2019-07-19
IL265617A (en) 2019-05-30
US20200039946A1 (en) 2020-02-06
LT3518927T (lt) 2021-01-25
ES2830749T3 (es) 2021-06-04
HUE052039T2 (hu) 2021-04-28
US11345673B2 (en) 2022-05-31
RU2019113064A (ru) 2020-10-30
SI3518927T1 (sl) 2021-01-29
RU2765102C2 (ru) 2022-01-25
CA3038008A1 (en) 2018-04-05
IT201600098338A1 (it) 2018-03-30
BR112019006565A2 (pt) 2019-07-02

Similar Documents

Publication Publication Date Title
HRP20200819T1 (hr) Spojevi indol karboksamida korisni kao inhibitori kinaze
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2019506430A5 (hr)
HRP20170352T1 (hr) Spojevi bis(fluroalkil)-1,4-benzodiazepinona kao notch inhibitori
CY1118292T1 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
ME01089B (me) Derivat benzimidazola i njegova upotreba kao antagonista receptora aii
JP2006524660A5 (hr)
AR081337A1 (es) Derivados de 1,4-benzotiazepinas, composiciones farmaceuticas que los comprenden y su uso en la preparacion de un medicamento para el tratamiento de trastornos metabolicos
HRP20120735T1 (hr) Derivati fosfonske kiseline i njihova uporaba kao antagonista p2y12 receptora
AR062886A1 (es) Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
JP2012530765A5 (hr)
CY1116190T1 (el) Φαρμακευτικη συνθεση η οποια περιεχει οπτικα ενεργη ενωση που διαθετει δραστικοτητα αγωνιστη υποδοχεα θρομβοποιητινης και ενδιαμεσο γι' αυτην
ECSP099767A (es) Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas
JP2015521156A5 (hr)
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
PE20220964A1 (es) Derivados de n-metil, n-(6-(metoxi)piridazin-3-il) amina como moduladores de autotaxina (atx) para el tratamiento de enfermedades inflamatorias de las vias respiratorias o fibroticas
PE20210550A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico
HRP20120257T1 (hr) Antagonisti receptora 5-ht7
MX2009003283A (es) Nuevos derivados imidazolonas, su preparacion como medicamentos, composiciones farmaceuticas y uso como inhibidores de proteinas quinasas, principalmente cdc7.
BR112021023765A2 (pt) Composto de fórmula (1), um isômero óptico, uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, inibidor de aurora quinase, composição farmacêutica de combinação e aplicação do composto
RU2009146132A (ru) Карбамоилоксиарилалканоиларилпиперазиновое соединение, фармацевтические композиции, содержащие его, и способ лечения боли, беспокойства и депрессии
HRP20201769T1 (hr) Spojevi 1-fenilpropanona i njihove uporabe
JP2015534567A5 (hr)
HRP20161024T1 (hr) Novi derivati amino-pirolina i njihova uporaba u sprječavanju i/ili liječenju metaboličkog sindroma